Hypervascular Tumors clinical trials at University of California Health
2 in progress, 0 open to eligible people
Instylla HES Hypervascular Tumor Pivotal Study
Sorry, in progress, not accepting new patients
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.
at UC Irvine UCLA
Obsidio™ Conformable Embolic Registry
Sorry, not currently recruiting here
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
at UCLA
Our lead scientists for Hypervascular Tumors research studies include Siddarth Padia, MD.
Last updated: